8-K 1 b72696oie8vk.htm OXIGENE, INC. e8vk
Table of Contents

 
 
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 22, 2008
OXiGENE, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other
jurisdiction of
incorporation) 		  0-21990
(Commission File
Number) 		  13-3679168
(I.R.S. Employer
Identification No.)
230 Third Avenue, Waltham, MA 02451
(Address of principal executive offices)
Registrant’s telephone number, including area code: (781) 547-5900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
SIGNATURE

Table of Contents

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(a), (c) - (f) Not applicable.
(b) Effective as of October 22, 2008, David Chaplin, Ph.D., Chief Scientific Officer of OXiGENE, Inc., and J. Richard Zecher, Ph.D. resigned from OXiGENE’s Board of Directors. Dr. Chaplin will continue in his role as OXiGENE’s Chief Scientific Officer. Dr. Chaplin and Dr. Zecher resigned from OXiGENE’s Board to allow OXiGENE to maintain compliance with the Board composition requirements of The NASDAQ Stock Market. OXiGENE noted its appreciation of Dr. Chaplin’s and Dr. Zecher’s service on its Board of Directors.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: October 27, 2008  OXiGENE, Inc.
 		  
  /s/ James B. Murphy    
  By: James B. Murphy   
  Vice President and Chief Financial Officer